Bristol-Myers Squibb Company
Patent Legal Department
Princeton, NJ 08543-4000

FACSIMILE TRANSMISSION SHEET

IN RE APPLICATION OF
ATWAL ET AL.
APPLICATION NO: 10/660,878
FILED: SEPTEMBER 12, 2003
FOR: HETEROCYCLIC DIHYDROPYRIMIDINE COMPOUNDS

DATE OF TRANSMISSION:	December 16, 2004
TO:	Examiner Deepak Rao Art Unit 1624
PTO FACSMILE NO:	**571-273-8300**
NUMBER OF PAGES:	(6, including cover sheet) INFORMATION DISCLOSURE STATEMENT
FROM:	Bristol-Myers Squibb Company ATTN: Deanna L. Baxam
RETURN FACSIMILE NO.:	(609) 252-4526

This communication is being filed in the United States Patent and Trademark Office by facsimile transmission according to the provisions of 37 C.F.R. § 1.6(d). The sender acknowledges that the receipt date accorded to the correspondence will be the date on which the complete transmission is received in the Patent and Trademark Office. As required, the application number of the patent or application is entered as a part of the sender's identification above.

If all pages of this transmission are not received, please immediately contact:

Tina Markee @ (609) 252-4300; or
Deanna L. Baxam @ (609) 252-4014.

DEC 16 2004

CASE HA0726DIV

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below by facsimile transmission to the Official PTO Fax Number, (571) 273-8300.

Deanna Baxam	Deanna Baxam	December 16, 2004
Type or print name	Signature	Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
LLOYD ET AL.
APPLICATION NO: 10/660,878
FILED: SEPTEMBER 12, 2003
FOR: HETEROCYCLO DIHYDROPYRIMIDINE COMPOUNDS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

To the extent they were not previously submitted, copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

The Commissioner is authorized to charge any fee deemed necessary, or credit any overpayment thereof, to the assignee's Deposit Account Number 19-3880.

Respectfully submitted,



Deanna L. Baxam
Attorney for Applicants
Reg. No. 45,266

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4014

Date: December 16, 2004

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

S.N. 10/[illegible],478

Atty Docket No. HA726DIV

Group 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM						☐	☐
	AN						☐	☐
	AO						☐	☐
	AP						☐	☐
	AQ						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Cochran et al., "Regionally selective alterations in local cerebral glucose utilization evoked by charybdotoxin, a blocker of central voltage-activated K+-channels," Eur J Neurosci. 2001 Nov;14(9):1455-63;
	AS	Coleman et al., "Subunit composition of Kv1 channels in human CNS," J Neurochem. 1999 Aug;73(2):849-58;
	AT	Davies et al., "Kv channel subunit expression in rat pulmonary arteries," Lung. 2001;179(3):147-61. Epub 2002 Feb 04;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

S.N. 10/29[illegible]

Atty. Docket No. HA726DIV

Group 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AA	Frey et al., "Blocking of cloned and native delayed rectifier K channels from visceral smooth muscles by phencyclidine," Neurogastroenterol Motil. 2000 Dec;12(6):509-16;
	AB	Hanson et al., "UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation," British Journal of Pharmacology (1999), 126, 1707-1716;
	AC	Hatton et al., "Functional and molecular expression of a voltage-dependent K(+) channel (Kv1.1) in interstitial cells of Cajal," J Physiol. 2001 Jun 1;533 (Pt 2):315-27;
	AD	Koh et al., "Contribution of delayed rectifier potassium currents to the electrical activity of murine colonic smooth muscle," J Physiol. 1999 Mar 1; 515 (Pt 2):475-87.
	AE	Kourrich et al., "Kaliotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats," Behav Brain Res. 2001 Apr 8;120(1):35-46.
	AF	Lopantsev et al., "Hyperexcitability of CA3 pyramidal cells in mice lacking the potassium channel subunit Kv1.1," Epilepsia. 2003 Dec;44(12):1506-12;
	AG	MacDonald et al., "Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion," Mol Endocrinol. 2001 Aug;15(8):1423-35;
	AH	MacDonald et al., "Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets," Diabetologia. 2003 Aug;46(8):1046-62. Epub 2003 Jun 27.
	AI	Pozeg et al., "In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats," Circulation. 2003 Apr 22;107(15):2037-44. Epub 2003 Apr 14.
	AJ	Rho et al., "Developmental seizure susceptibility of kv1.1 potassium channel knockout mice," Dev Neurosci. 1999 Nov;21(3-5):320-7;
	AK	Shah et al., "Immunosuppressive effects of a Kv1.3 inhibitor," Cellular Immunology 221, (2003), 100-106.
	AL	Vianna-Jorge et al., "Shaker-type Kv1 channel blockers increase the peristaltic activity of guinea-pig ileum by stimulating acetylcholine and tachykinins release by the enteric nervous system," Br J Pharmacol. 2003 Jan; 138(1):57-62;
	AM	Wickenden, "Potassium channels as anti-epileptic drug targets," Neuropharmacology. 2002 Dec;43(7):1055-60.
	AN	Wulff et al., "Potassium channels as therapeutic targets for autoimmune disorders," Current Opinion in Drug Discovery & Development 2003 6(5):640-647.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Ser. No. 10/600,678
Atty Docket No. HA776Div

Group 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AA	Xu et al., "The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity," Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3112-7. Epub 2004 Feb 23 (epublished 2004 Feb 23);
	AB	
	AC	
	AD	
	AE	
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.